ETV1 is a sequence-specific DNA-binding transcription factor that recognizes the consensus pentanucleotide 5'-CGGA[AT]-3' and functions as a transcriptional activator of RNA polymerase II 1. In cardiac tissue, ETV1 activates a rapid conduction transcriptional program by directly promoting expression of genes encoding rapid conduction properties, including Scn5a, Gja5, and Nkx2-5 2. ETV1 is essential for cardiac conduction specification; cardiomyocyte-specific ETV1 deletion results in conduction abnormalities and His-Purkinje system hypoplasia, while forced ETV1 expression converts ventricular myocytes toward a His-Purkinje phenotype 2. During cardiac pressure overload associated with heart failure, ETV1 expression is downregulated in the left atrium, contributing to electrical remodeling and profibrotic gene activation 3. In cancer, ETV1 is frequently dysregulated through gene fusion events. Approximately 50% of prostate cancers harbor ETV1 gene fusions with TMPRSS2, resulting in androgen-responsive overexpression of ETV1 4, with ETV1 fusions defining a major molecular subtype alongside ERG and FLI1 5. ETV1 also shows copy number gains in pancreatic adenocarcinoma progression and metastasis 6. ETV1 chr7 translocations drive Ewing sarcoma carcinogenesis 7, where ETV1 and related PEA3 subfamily proteins promote cell proliferation, motility, and invasion through complex post-translational modifications 7.